Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula

Get In Touch

Quick Email
info.help@gmail.com
  • Home |
  • Scholar Rock ditches Novo’s legacy Catalent plant in FDA refiling of SMA drug

Scholar Rock ditches Novo’s legacy Catalent plant in FDA refiling of SMA drug

  • August 10, 2026

Scholar Rock has dropped Novo Nordisk’s troubled Catalent facility as a contract manufacturer in its FDA refiling for apitegromab, a spinal muscular atrophy candidate, after a recent inspection of the plant was classified as “Official Action Indicated.”

Leave A Comment

Fields (*) Mark are Required